Literature DB >> 7205631

Renal excretion of cimetidine.

I M Weiner, L Roth.   

Abstract

The renal excretion and certain pharmacokinetic properties of cimetidine were studied in anesthetized rats undergoing moderate osmotic diuresis. When cimetidine concentrations in plasma (Pcim) were low, ca. 2 micrograms/ml, the clearance of cimetidine (Ccim) was 2.64-fold greater than the glomerular filtration rate (GFR). Ccim was lower at higher concentrations, e.g., at ca. 200 micrograms/ml, Ccim/GFR was 1.24. When animals with low Pcim were alkalotic (bicarbonate infusion), Ccim/GFR was 1.82 (different from control, P less than 0.01). In nonalkalotic animals, Ccim/GFR was not influenced by changes in urine flow rate. High levels of Pcim completely blocked net secretion of the cation, tetraethylammonium ion, but did not inhibit the secretion of the anion p-aminohippurate. The half-time of cimetidine in plasma was 43 to 49 min. The apparent volume of distribution was 3.6-fold greater than estimated total body water. We conclude that cimetidine is secreted by the renal organic cation transport mechanism and that it probably undergoes passive reabsorption (nonionic diffusion) to a modest extent when the urine is alkaline. The relatively long half-life of the drug in the body, despite its very high renal clearance, is attributable to the large volume of distribution.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7205631

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

2.  Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats.

Authors:  E F Foote; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 3.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

Review 4.  Renal transport of drugs: an overview of methodology with application to cimetidine.

Authors:  K M Giacomini; P H Hsyu; L G Gisclon
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

5.  The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens.

Authors:  Gary W Caldwell; David M Ritchie; John A Masucci; William Hageman; Carlos Cotto; Jeffrey Hall; Becki Hasting; William Jones
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

6.  Altered flecainide disposition in healthy volunteers taking quinine.

Authors:  A Munafo; G Reymond-Michel; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats.

Authors:  I Yano; T Ito; M Takano; K Inui
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

8.  Selective inhibition of acetaminophen oxidation and toxicity by cimetidine and other histamine H2-receptor antagonists in vivo and in vitro in the rat and in man.

Authors:  M C Mitchell; S Schenker; K V Speeg
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

9.  Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide.

Authors:  A Maiza; P T Daley-Yates
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

10.  Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.

Authors:  Marie-Laure Boof; Atef Halabi; Mike Ufer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2019-12-13       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.